A Multicenter, Phase II, Neoadjuvant And Adjuvant Study Of Multiple Therapies In Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer (NAUTIKA1)

This trial will evaluate the efficacy and safety of various therapies in patients with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated non-small cell lung cancer (NSCLC) tumors that meet protocol-specified biomarker criteria.

Study ID: 2225
NCT Number: NCT04302025
Principal Investigator: Jussuf Kaifi, MD
Department: Surgery-Cardiothoracic
Eligibility: Both men and women 18 years old to 100 years old. Does not accept healthy volunteers.

For questions about this study, please contact:

CancerClinicalTrials@health.missouri.edu

Conditions & Treatments

Doctors

Locations

Pages

Study Protocol 2225

A Multicenter, Phase II, Neoadjuvant And Adjuvant Study Of Multiple Therapies In Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer (NAUTIKA1)